Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients

被引:74
作者
Duranay, Murat
Akay, Hatice
Yilmaz, Fatma Meric
Senes, Mehmet
Tekeli, Nurcin
Yucel, Dogan
机构
[1] Ankara Hosp, Dialysis Unit, Minist Hlth, TR-06340 Ankara, Turkey
[2] Ankara Hosp, Clin Biochem Lab, Minist Hlth, TR-06340 Ankara, Turkey
关键词
CRP; haemodialysis; inflammation; L-carnitine; nutrition;
D O I
10.1093/ndt/gfl356
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Carnitine loss through dialysis membranes is shown to be related to the lack of carnitine in long-term haemodialysis patients. It has been previously reported that haemodialysis patients might have benefited from carnitine supplementation. Methods. A total of 21 chronic haemodialysis patients maintaining carnitine supplementation and 21 controls (haemodialysis patients not receiving carnitine) were included in the study. l-carnitine was used intravenously three times a week after each haemodialysis session, at a 20 mg/kg dose. C-reactive protein (CRP), lipid profile, transferrin, total protein and albumin levels were determined at baseline after 3 and 6 months of treatment, and compared with the control group. Results. CRP levels were significantly decreased in carnitine group in contrast to the increase in the control group. Transferrin, total protein and albumin levels and body mass index (BMI) of the patients rose in the carnitine group. Conclusions. There was a significant benefit of l-carnitine on CRP, transferrin, total protein and albumin levels of the haemodialysis patients.
引用
收藏
页码:3211 / 3214
页数:4
相关论文
共 22 条
[1]   MULTICENTER TRIAL OF L-CARNITINE IN MAINTENANCE HEMODIALYSIS-PATIENTS .2. CLINICAL AND BIOCHEMICAL EFFECTS [J].
AHMAD, S ;
ROBERTSON, HT ;
GOLPER, TA ;
WOLFSON, M ;
KURTIN, P ;
KATZ, LA ;
HIRSCHBERG, R ;
NICORA, R ;
ASHBROOK, DW ;
KOPPLE, JD .
KIDNEY INTERNATIONAL, 1990, 38 (05) :912-918
[2]   Role of carnitine in modulating acute-phase protein synthesis in hemodialysis patients [J].
Bellinghieri, G ;
Santoro, D ;
Calvani, M ;
Savica, V .
JOURNAL OF RENAL NUTRITION, 2005, 15 (01) :13-17
[3]  
Caruso U, 1998, DIALYSIS TRANSPLANT, V27, P498
[4]  
Chazot C, 2003, CLIN NEPHROL, V59, P24
[5]  
Dawson B, 2004, BASIC CLIN BIOSTATIS, P69
[6]  
Eikelboom JW, 2001, CURR OPIN NEPHROL HY, V15, P81
[7]   Dialysis-related carnitine disorder and levocarnitine pharmacology [J].
Evans, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :S13-S26
[8]   Effect of oral L-carnitine on serum myoglobin in hemodialysis patients [J].
Feinfeld, DA ;
Kurian, P ;
Cheng, JT ;
Dilimetin, G ;
Arriola, MR ;
Ward, L ;
Manis, T ;
Carvounis, CP .
RENAL FAILURE, 1996, 18 (01) :91-96
[9]   Hyperhomocysteinemia and end-stage renal disease: Determinants and association with cardiovascular disease in Tunisian patients [J].
Fellah, H ;
Feki, M ;
Hsairi, M ;
Sanhaji, H ;
Kaabachi, N ;
Ben Abdallah, T ;
Massy, ZA ;
Ben Maiz, H ;
Lacour, B ;
Mebazaa, A .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (05) :675-680
[10]  
Foley RN, 1998, J AM SOC NEPHROL, V9, P267